Market Cap 25.16M
Revenue (ttm) 640,000.00
Net Income (ttm) -69.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,921.88%
Debt to Equity Ratio -0.90
Volume 846,569
Avg Vol 1,068,714
Day's Range N/A - N/A
Shares Out 31.31M
Stochastic %K 5%
Beta 0.31
Analysts Strong Sell
Price Target $14.60

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 475 238 6837
Address:
555 Long Wharf Drive, 12th Floor, New Haven, United States
CoffeeRocks
CoffeeRocks Aug. 24 at 5:35 PM
$INO buys at 1$ $IOVA $BTAI $ATAI Could become 6-7!
0 · Reply
Paxhawig
Paxhawig Aug. 24 at 5:28 PM
$BTAI this bitch is short
1 · Reply
SrTxan
SrTxan Aug. 24 at 5:25 PM
$BTAI That’s exactly what your life needs: someone to take control of you through a distressed-debt conversion… into a bull.
1 · Reply
Paxhawig
Paxhawig Aug. 24 at 4:53 PM
$BTAI Distressed‑Debt‑Takeover
0 · Reply
Tonyboner
Tonyboner Aug. 24 at 4:34 PM
$BTAI New lows with higher than normal volume is not a good sign.
0 · Reply
Tonyboner
Tonyboner Aug. 24 at 1:50 PM
$BTAI Just horrid mgnt no update to share holders just letting it bleed.
1 · Reply
zillionaire17
zillionaire17 Aug. 24 at 12:43 PM
$BTAI "Any chance goes full meme stock on the 28th? What do you guys think?"🔥🔥🔥🔥🔥🔥🔥🚀🚀🚀🚀🚀🚀🚀
1 · Reply
skullfox
skullfox Aug. 24 at 12:28 PM
0 · Reply
Paxhawig
Paxhawig Aug. 24 at 12:13 PM
$BTAI today should 1.8
1 · Reply
sagasta29
sagasta29 Aug. 24 at 11:54 AM
$BTAI same words as in the 11th amendment… tic toc
0 · Reply
Latest News on BTAI
BioXcel Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 11 days ago

BioXcel Therapeutics Quarterly report: Q2 2026


BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)

2026-05-15T12:03:32.000Z - 3 months ago

BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)


BioXcel Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Quarterly report: Q1 2026


BioXcel Therapeutics Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Earnings release: Q1 2026


BioXcel Therapeutics Transcript: Investor update

Apr 23, 2026, 2:00 PM EDT - 4 months ago

BioXcel Therapeutics Transcript: Investor update


BioXcel Therapeutics Slides: Investor update

Apr 23, 2026, 2:00 PM EDT - 4 months ago

BioXcel Therapeutics Slides: Investor update


BioXcel Therapeutics enrolls first patients in BXCL501 trial

2026-04-08T11:09:11.000Z - 4 months ago

BioXcel Therapeutics enrolls first patients in BXCL501 trial


BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA

2026-04-01T11:09:26.000Z - 5 months ago

BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA


BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)

2026-03-27T11:20:13.000Z - 5 months ago

BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)


BioXcel Therapeutics Annual report: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 5 months ago

BioXcel Therapeutics Annual report: Q4 2025


BioXcel Therapeutics Earnings release: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 5 months ago

BioXcel Therapeutics Earnings release: Q4 2025


BioXcel price target lowered to $6 from $10 at H.C. Wainwright

2026-03-05T13:59:23.000Z - 6 months ago

BioXcel price target lowered to $6 from $10 at H.C. Wainwright


BioXcel Therapeutics Transcript: Status update

Feb 27, 2026, 2:00 PM EST - 6 months ago

BioXcel Therapeutics Transcript: Status update


BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi

2026-01-20T12:06:39.000Z - 7 months ago

BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi


BioXcel Therapeutics appoints Pavao as acting CCO

2026-01-12T12:21:09.000Z - 8 months ago

BioXcel Therapeutics appoints Pavao as acting CCO


BioXcel Therapeutics Transcript: AGM 2025

Dec 12, 2025, 9:00 AM EST - 9 months ago

BioXcel Therapeutics Transcript: AGM 2025


BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)

2025-11-12T12:16:09.000Z - 10 months ago

BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)


BioXcel Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Quarterly report: Q3 2025


BioXcel Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Earnings release: Q3 2025


BioXcel Therapeutics Proxy statement: Proxy Filing

Nov 12, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Proxy statement: Proxy Filing


BioXcel Therapeutics Proxy statement: Proxy Filing

Oct 31, 2025, 8:00 AM EDT - 10 months ago

BioXcel Therapeutics Proxy statement: Proxy Filing


BioXcel Therapeutics regains compliance with Nasdaq

2025-09-18T11:11:17.000Z - 1 year ago

BioXcel Therapeutics regains compliance with Nasdaq


BioXcel Therapeutics Transcript: Study Result

Sep 10, 2025, 2:00 PM EDT - 1 year ago

BioXcel Therapeutics Transcript: Study Result


BioXcel Therapeutics Press release: Study Result

Sep 10, 2025, 2:00 PM EDT - 1 year ago

BioXcel Therapeutics Press release: Study Result


BioXcel Therapeutics Slides: Study Result

Sep 10, 2025, 2:00 PM EDT - 1 year ago

BioXcel Therapeutics Slides: Study Result


BioXcel Therapeutics Transcript: Study Update

Aug 27, 2025, 8:00 AM EDT - 1 year ago

BioXcel Therapeutics Transcript: Study Update


BioXcel Therapeutics Press release: Study Update

Aug 27, 2025, 8:00 AM EDT - 1 year ago

BioXcel Therapeutics Press release: Study Update


BioXcel Therapeutics Slides: Study Update

Aug 27, 2025, 8:00 AM EDT - 1 year ago

BioXcel Therapeutics Slides: Study Update


BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:29 AM EDT - 1 year ago

BioXcel's agitation drug meets main goal in at-home study


BioXcel Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Quarterly report: Q2 2025


BioXcel Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q2 2025


BioXcel Therapeutics Quarterly report: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Quarterly report: Q1 2025


BioXcel Therapeutics Earnings release: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q1 2025


BioXcel Therapeutics Annual report: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Annual report: Q4 2024


BioXcel Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q4 2024


BioXcel Therapeutics Announces Reverse Stock Split

Feb 6, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Reverse Stock Split


BioXcel Therapeutics Proxy statement: Proxy Filing

Dec 30, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Proxy statement: Proxy Filing


BioXcel Therapeutics Proxy statement: Proxy Filing

Dec 18, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Proxy statement: Proxy Filing


BioXcel Therapeutics Announces Proposed Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering


BioXcel Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2024


BioXcel Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Quarterly report: Q3 2024


BioXcel Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings release: Q3 2024


BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference


CoffeeRocks
CoffeeRocks Aug. 24 at 5:35 PM
$INO buys at 1$ $IOVA $BTAI $ATAI Could become 6-7!
0 · Reply
Paxhawig
Paxhawig Aug. 24 at 5:28 PM
$BTAI this bitch is short
1 · Reply
SrTxan
SrTxan Aug. 24 at 5:25 PM
$BTAI That’s exactly what your life needs: someone to take control of you through a distressed-debt conversion… into a bull.
1 · Reply
Paxhawig
Paxhawig Aug. 24 at 4:53 PM
$BTAI Distressed‑Debt‑Takeover
0 · Reply
Tonyboner
Tonyboner Aug. 24 at 4:34 PM
$BTAI New lows with higher than normal volume is not a good sign.
0 · Reply
Tonyboner
Tonyboner Aug. 24 at 1:50 PM
$BTAI Just horrid mgnt no update to share holders just letting it bleed.
1 · Reply
zillionaire17
zillionaire17 Aug. 24 at 12:43 PM
$BTAI "Any chance goes full meme stock on the 28th? What do you guys think?"🔥🔥🔥🔥🔥🔥🔥🚀🚀🚀🚀🚀🚀🚀
1 · Reply
skullfox
skullfox Aug. 24 at 12:28 PM
0 · Reply
Paxhawig
Paxhawig Aug. 24 at 12:13 PM
$BTAI today should 1.8
1 · Reply
sagasta29
sagasta29 Aug. 24 at 11:54 AM
$BTAI same words as in the 11th amendment… tic toc
0 · Reply
JOEYD05
JOEYD05 Aug. 24 at 11:09 AM
$BTAI sounds like a buyout or merger is imminent!
2 · Reply
Paxhawig
Paxhawig Aug. 24 at 11:07 AM
$BTAI https://ir.bioxceltherapeutics.com/sec-filings/sec-filing/8-k/0001104659-26-099900
0 · Reply
Paxhawig
Paxhawig Aug. 24 at 11:05 AM
$BTAI bullshit extended
0 · Reply
Paxhawig
Paxhawig Aug. 24 at 8:05 AM
$BTAI bloody day
0 · Reply
Daniech0514
Daniech0514 Aug. 24 at 2:45 AM
$BTAI would be nice to see this be the next cdtx....1:20 reverse split and then get bought out years later for $220/share. But I highly doubt it. Probably end up more like BLUE.
1 · Reply
SrTxan
SrTxan Aug. 23 at 11:28 AM
$BTAI Here’s my Sunday table. Apparently, financial analysis isn’t that difficult after all. Disclaimer: Price ranges calculated using the highly respected "pick a random percentage and put it in a table" valuation method. These are not price targets.
1 · Reply
SrTxan
SrTxan Aug. 23 at 11:01 AM
$BTAI Hahaha, this just keeps getting better. You take $0.80, decide that an extension is worth +40%, a deal +250%, another one +600%, and a buyout $6+… and there we have it: Sunday’s grand financial analysis! I have to say, I do enjoy seeing you so dedicated, working even on a Sunday. Now that’s commitment. Although, to be fair, you’re not exactly exhausting yourself, you even use AI to make the table for you. Now try doing it all by yourself and let’s see what prices you come up with when ChatGPT isn’t doing your homework. And just out of curiosity... do they pay you extra to work from home on Sundays, or is this simply a labor of love? Because to conclude ...if something good happens, it goes up, if something really good happens, it goes up a lot, you probably didn’t need to put together this little homemade table. You’ve even managed to get Toni up early. Hahahaha.
1 · Reply
Paxhawig
Paxhawig Aug. 23 at 9:51 AM
1 · Reply
SrTxan
SrTxan Aug. 22 at 10:07 PM
$BTAI The difference between you and me, Ernesto? I can afford to wait a lifetime for BTAI. You have to pay borrow fees every single day just to keep your short positions open while the clock keeps running. No wonder you even have to work overtime on weekends. Your short position apparently doesn’t believe in days off. And now, every once in a while, I even see you posting positive news about the stock. Add Friday’s fake premarket pump with no volume, and it tells me one thing: you shorts need fresh liquidity. Funny how your narrative suddenly changes when things don’t go the way you wanted, isn’t it?
1 · Reply
Paxhawig
Paxhawig Aug. 22 at 7:02 PM
$BTAI Funny 66 :-) https://www.gurufocus.com/news/2944395/lucid-capital-sees-promising-future-for-bioxcel-therapeutics-btai-btai-stock-news
1 · Reply
DylanGFM
DylanGFM Aug. 22 at 12:56 PM
$BTAI As optimistic as I'd like to be, Its been way too damn long keeping this on the back burner watching, checking here and there to see if any action or anything good is to come out of this. Way too long of yet again another down trend. Unless they have something in the works thats going to get them out of debt...😬..... But I will say from a technical momentum trader/scalpers pov, we could have a no reason technical break out to scalp up to the 200 EMA if some random volume wants to show up. Most likely for absolutely no reason, and then short it back down. Don't hold your breath.
2 · Reply
USAEquityResearch
USAEquityResearch Aug. 22 at 8:55 AM
$BTAI 📊 USAEquityResearch ▲ 0.80 (+0.63%) Trend: Bearish 📉 RSI (14): 47.5 — neutral territory MACD: bearish, below signal line Volume: above average 📌 Key Levels Resistance: 1.19 | Support: 0.79 20-MA: 0.89 | 50-MA: 1.01 💼 Fundamentals Mkt Cap: $25.16M FCF: $-31.75M (-1.01/sh) Total Debt: $104.45M Educational content only. Not financial advice.
0 · Reply